COMPANY
JiLLiON Therapeutics Inc.
NIH awards 5
- NIH award 2R44AG085856-02 FY2026: $1,118,025 awarded for that fiscal year; activity R44 (SBIR); PI FLAJOLET, MARC; recipient as written: JILLION THERAPEUTICS INC., BROOKLYN, NY. Advancing DEL-derived Small Molecule I source ↗
- NIH award 1R43DA061909-01 FY2025: $398,093 awarded for that fiscal year; activity R43 (SBIR); PI FLAJOLET, MARC; recipient as written: JILLION THERAPEUTICS INC., BROOKLYN, NY. Identification of therapeutic molecules source ↗
- NIH award 1R43DA062975-01 FY2025: $399,483 awarded for that fiscal year; activity R43 (SBIR); PI FLAJOLET, MARC; recipient as written: JILLION THERAPEUTICS INC., BROOKLYN, NY. Synergy between Artificial Intelligence source ↗
- NIH award 1R43DA061688-01 FY2024: $399,884 awarded for that fiscal year; activity R43 (SBIR); PI FLAJOLET, MARC; recipient as written: JILLION THERAPEUTICS INC., BROOKLYN, NY. The use of DNA-encoded library (DEL) tec source ↗
- NIH award 1R43AG085856-01A1 FY2024: $496,373 awarded for that fiscal year; activity R43 (SBIR); PI FLAJOLET, MARC; recipient as written: JILLION THERAPEUTICS INC., BROOKLYN, NY. Targeting biologically relevant tau mo source ↗
Funding and NIH signals
- NIH award NIH awarded $1.12M (SBIR Phase II 2R44AG085856-02, competing renewal, notice Sep 17, 2026). NIH RePORTER 2R44AG085856-02 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 2R44AG085856-02
Organization: JILLION THERAPEUTICS INC.; City/State: BROOKLYN, NY; Project number: 2R44AG085856-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1118025; Administering IC: National Institute on Aging; Project title: Advancing DEL-derived Small Molecule Inhibitors of Pathological Tau Toward Preclinical Development for Alzheimer’s Disease and Tauopathies; Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 2R44AG085856-02